Regeneron Pharmaceuticals Inc (REGN)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 4,779,900 | 4,199,300 | 4,858,800 | 9,325,800 | 3,810,400 |
| Revenue | US$ in thousands | 14,202,000 | 13,044,200 | 12,113,500 | 16,014,400 | 8,440,200 |
| Pretax margin | 33.66% | 32.19% | 40.11% | 58.23% | 45.15% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $4,779,900K ÷ $14,202,000K
= 33.66%
Regeneron Pharmaceuticals Inc's pretax margin has exhibited a varying trend over the period from December 31, 2020, to December 31, 2024. The pretax margin stood at 45.15% in December 2020, reflecting the company's ability to generate a net profit before accounting for taxes. Subsequently, there was a notable increase in the pretax margin to 58.23% by December 2021, indicating an improvement in the company's operational efficiency and profitability.
However, there was a decline in the pretax margin to 40.11% by December 2022, followed by a further decrease to 32.19% by December 2023. These reductions suggest potential challenges faced by Regeneron Pharmaceuticals Inc in managing costs or sustaining revenue growth during these periods.
In the most recent data available, as of December 31, 2024, the pretax margin recovered slightly to 33.66%, indicating a modest improvement compared to the previous year. Overall, fluctuations in the pretax margin reflect the company's performance in generating profits relative to its total revenue before the impact of taxes, highlighting the importance of effective cost management and revenue growth strategies for sustainable financial success.
Peer comparison
Dec 31, 2024